Phase II study of gefitinib and inserted cisplatin plus docetaxel as a first-line treatment for advanced non-small cell lung cancer haboring an epidermal growth factor receptor activating mutation

被引：0
|
作者：
Kanda, Shintaro
Ohe, Yuichiro
Horinouchi, Hidehito
Fujiwara, Yutaka
Nokihara, Hiroshi
Yamamoto, Noboru
Sekine, Ikuo
Kunitoh, Hideo
Kubota, Kaoru
Tamura, Tomohide
机构：
[1] Natl Canc Ctr, Div Thorac Oncol, Tokyo, Japan
[2] Natl Canc Ctr Hosp East, Div Thorac Oncol, Kashiwa, Chiba, Japan
[3] Chiba Univ, Dept Med Oncol, Chiba, Japan
[4] Mitsui Mem Hosp, Dept Resp Med, Tokyo 101, Japan
[5] Nippon Med Coll Hosp, Div Pulm Med Infect & Oncol, Dept Internal Med, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8064
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase II trial of carboplatin, S-1, and gefitinib as first-line triplet chemotherapy for advanced non-small cell lung cancer patients with activating epidermal growth factor receptor mutations
    Tamiya, Akihiro
    Tamiya, Motohiro
    Shiroyama, Takayuki
    Saijo, Nobuhiko
    Nakatani, Takeshi
    Minomo, Shojiro
    Tsuji, Taisuke
    Takeuchi, Naoko
    Omachi, Naoki
    Kurata, Kanako
    Suzuki, Hidekazu.
    Okamoto, Norio
    Okishio, Kyoichi
    Hirashima, Tomonori
    Atagi, Shinji
    [J]. MEDICAL ONCOLOGY, 2015, 32 (03) : 1 - 7
  • [22] A phase II study of gefitinib in combination with S-1 plus carboplatin as first-line chemotherapy for patients with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations
    Tamiya, Akihiro
    Tamiya, Motohiro
    Nakatani, Akeshi
    Shiroyama, Talcayuki
    Kitai, Kanako
    Tsuji, Taisuke
    Morishita, Naoko
    Omachi, Naold
    Asami, Kazuhiro
    Okamoto, Norio
    Suzuki, Hidekazu
    Okishio, Kyoichi
    Kawaguchi, Tomoya
    Hiroshima, Tomonort
    Atagi, Shinji
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [23] Phase II trial of carboplatin, S-1, and gefitinib as first-line triplet chemotherapy for advanced non-small cell lung cancer patients with activating epidermal growth factor receptor mutations
    Akihiro Tamiya
    Motohiro Tamiya
    Takayuki Shiroyama
    Nobuhiko Saijo
    Takeshi Nakatani
    Shojiro Minomo
    Taisuke Tsuji
    Naoko Takeuchi
    Naoki Omachi
    Kanako Kurata
    Hidekazu. Suzuki
    Norio Okamoto
    Kyoichi Okishio
    Tomonori Hirashima
    Shinji Atagi
    [J]. Medical Oncology, 2015, 32
  • [24] EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION TESTING AND FIRST LINE TREATMENT WITH GEFITINIB IS A DOMINANT STRATEGY IN THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Lopes, de Lima G.
    [J]. VALUE IN HEALTH, 2011, 14 (03) : A166 - A166
  • [25] The evolving first-line treatment of advanced non-small cell lung cancer harbouring epidermal growth factor receptor mutations
    Decoster, Lore
    Giron, Philippe
    Mignon, Sacha
    De Greve, Jacques
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2018, 7 : S134 - S137
  • [26] FIRST LINE GEFITINIB IN YOUNGER PATIENTS WITH EPIDERMAL GROWTH FACTOR RECEPTOR MUTATED ADVANCED NON-SMALL CELL LUNG CANCER
    Elhidsi, Mia
    Hudoyo, Ahmad
    Andarini, Sita
    [J]. RESPIROLOGY, 2015, 20 : 100 - 100
  • [27] First-line gefitinib therapy for elder advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: Multicenter phase II trial (NEJ 003 study)
    Minegishi, Y.
    Maemondo, M.
    Okinaga, S.
    Morikawa, N.
    Inoue, A.
    Kobayashi, K.
    Harada, M.
    Hagiwara, K.
    Nukiwa, T.
    Gemma, A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [28] COST-EFFECTIVENESS OF EPIDERMAL GROWTH-FACTOR RECEPTOR MUTATION TESTING AND FIRST-LINE TREATMENT WITH GEFITINIB FOR ADVANCED NON-SMALL-CELL LUNG CANCER
    Lopes, G. de Lima
    Segel, J.
    Tan, D.
    Do, Y.
    Mok, T.
    Finkelstein, E.
    [J]. EJC SUPPLEMENTS, 2011, 9 (01): : 2 - 2
  • [29] Phase II trial of docetaxel and gefitinib as first-line therapy for elderly patients with advanced non-small cell lung cancer (ANSCLC).
    Williams, CC
    Haura, EB
    Antonia, SJ
    Chiappori, A
    Bepler, G
    Simon, GR
    Moffitt, HL
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 701S - 701S
  • [30] Survival analysis for older patients with epidermal growth factor receptor mutation-positive advanced non-small cell lung cancer after progression of first-line gefitinib
    Nie, Xin
    Zhang, Ping
    Cheng, Gang
    Wu, Xiao-Nan
    Li, Lin
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 (01) : 150 - 155
12345